SIGA appoints Dr. Jay K. Varma as EVP and Chief Medical Officer

SIGA TECHNOLOGIES INC

Dr. Varma appointed EVP and CMO, effective Sept 6, 2023; continues as board member.
Annual base salary $750,000; guaranteed bonus of $750,000 for 2023 (pro-rated) and 2024.
Initial term through Dec 31, 2024, with automatic one-year renewals unless notice given.
Severance includes base salary continuation, pro-rata bonus, 12-month COBRA, and accelerated equity vesting on qualifying termination.
Dr. Varma previously served on board since Nov 2022; former professor at Weill Cornell and CDC role in NYC COVID response.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Jay K. Varma

Executive Vice President and Chief Medical Officer

SIGA · SIGA TECHNOLOGIES INC

Effective: 2023-09-06
Filed: September 6, 2023, 7:59 PM ET

On September 6, 2023, SIGA Technologies, Inc. (the “Company”) issued a press release announcing the appointment of Dr. Jay K. Varma as Executive Vice President and Chief Medical Officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Jay K. Varma was appointed as Executive Vice President and Chief Medical Officer at SIGA TECHNOLOGIES INC.

Action: appointed
Role: Executive Vice President and Chief Medical Officer

Exact text from the filing

On September 6, 2023, SIGA Technologies, Inc. (the “Company”) issued a press release announcing the appointment of Dr. Jay K. Varma as Executive Vice President and Chief Medical Officer of the Company.

View on SEC.gov

SIGA TECHNOLOGIES INC filing history →

Source: SEC EDGAR

accession 0001140361-23-042810

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.